Cargando…
miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs
Gastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5–7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRN...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603477/ https://www.ncbi.nlm.nih.gov/pubmed/36293105 http://dx.doi.org/10.3390/ijms232012248 |
_version_ | 1784817559307026432 |
---|---|
author | Ravegnini, Gloria Nannini, Margherita Indio, Valentina Serrano, Cesar Gorini, Francesca Astolfi, Annalisa Di Vito, Aldo Morroni, Fabiana Pantaleo, Maria Abbondanza Hrelia, Patrizia Angelini, Sabrina |
author_facet | Ravegnini, Gloria Nannini, Margherita Indio, Valentina Serrano, Cesar Gorini, Francesca Astolfi, Annalisa Di Vito, Aldo Morroni, Fabiana Pantaleo, Maria Abbondanza Hrelia, Patrizia Angelini, Sabrina |
author_sort | Ravegnini, Gloria |
collection | PubMed |
description | Gastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5–7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRNA expression profile comparison of PDGFRA D842V mutant GISTs and PDGFRA with mutations other than D842V (non-D842V). miRNA expression profiling was carried out on 10 patients using a TLDA miRNA array. Then, miRNA expression was followed by bioinformatic analysis aimed at evaluating differential expression, pathway enrichment, and miRNA-mRNA networks. We highlighted 24 differentially expressed miRNAs between D842V and non-D842V GIST patients. Pathway enrichment analysis showed that deregulated miRNAs targeted genes that are mainly involved in the immune response pathways. The miRNA-mRNA networks highlighted a signature of miRNAs/mRNA that could explain the indolent behavior of the D842V mutated GIST. The results highlighted a different miRNA fingerprint in PDGFRA D842V GISTs compared to non-D842Vmutated patients, which could explain the different biological behavior of this GIST subset. |
format | Online Article Text |
id | pubmed-9603477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96034772022-10-27 miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs Ravegnini, Gloria Nannini, Margherita Indio, Valentina Serrano, Cesar Gorini, Francesca Astolfi, Annalisa Di Vito, Aldo Morroni, Fabiana Pantaleo, Maria Abbondanza Hrelia, Patrizia Angelini, Sabrina Int J Mol Sci Article Gastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5–7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRNA expression profile comparison of PDGFRA D842V mutant GISTs and PDGFRA with mutations other than D842V (non-D842V). miRNA expression profiling was carried out on 10 patients using a TLDA miRNA array. Then, miRNA expression was followed by bioinformatic analysis aimed at evaluating differential expression, pathway enrichment, and miRNA-mRNA networks. We highlighted 24 differentially expressed miRNAs between D842V and non-D842V GIST patients. Pathway enrichment analysis showed that deregulated miRNAs targeted genes that are mainly involved in the immune response pathways. The miRNA-mRNA networks highlighted a signature of miRNAs/mRNA that could explain the indolent behavior of the D842V mutated GIST. The results highlighted a different miRNA fingerprint in PDGFRA D842V GISTs compared to non-D842Vmutated patients, which could explain the different biological behavior of this GIST subset. MDPI 2022-10-14 /pmc/articles/PMC9603477/ /pubmed/36293105 http://dx.doi.org/10.3390/ijms232012248 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ravegnini, Gloria Nannini, Margherita Indio, Valentina Serrano, Cesar Gorini, Francesca Astolfi, Annalisa Di Vito, Aldo Morroni, Fabiana Pantaleo, Maria Abbondanza Hrelia, Patrizia Angelini, Sabrina miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title | miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title_full | miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title_fullStr | miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title_full_unstemmed | miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title_short | miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs |
title_sort | mirna expression may have implications for immunotherapy in pdgfra mutant gists |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603477/ https://www.ncbi.nlm.nih.gov/pubmed/36293105 http://dx.doi.org/10.3390/ijms232012248 |
work_keys_str_mv | AT ravegninigloria mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT nanninimargherita mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT indiovalentina mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT serranocesar mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT gorinifrancesca mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT astolfiannalisa mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT divitoaldo mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT morronifabiana mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT pantaleomariaabbondanza mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT hreliapatrizia mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists AT angelinisabrina mirnaexpressionmayhaveimplicationsforimmunotherapyinpdgframutantgists |